Seminars
October 2025
Spike train structure of cortical transcriptomic populations in vivo
Kenneth Harris· UCL, UK
Wed, Oct 29 · 12:15 UTC · Online
The cortex comprises many neuronal types, which can be distinguished by their transcriptomes: the sets of genes they express. Little is known about the in vivo activity of these cell types, particularly as regards the structure of their spike trains, which might provide clues to cortical circuit function. To address this question, we used Neuropixels electrodes to record layer 5 excitatory populations in mouse V1, then transcriptomically identified the recorded cell types. To do so, we performed a subsequent recording of the same cells using 2-photon (2p) calcium imaging, identifying neurons between the two recording modalities by fingerprinting their responses to a “zebra noise” stimulus and estimating the path of the electrode through the 2p stack with a probabilistic method. We then cut brain slices and performed in situ transcriptomics to localize ~300 genes using coppaFISH3d, a new open source method, and aligned the transcriptomic data to the 2p stack. Analysis of the data is ongoing, and suggests substantial differences in spike time coordination between ET and IT neurons, as well as between transcriptomic subtypes of both these excitatory types.
July 2025
Cause & Consequences of neuronal Tau protein ‘activation’
Susanne Wegmann· German Center for Neurodegenerative Diseases (DZNE), Berlin
Thu, Jul 17 · 16:15 UTC · Online
June 2025
Expanding mechanisms and therapeutic targets for neurodegenerative disease
Aaron D. Gitler· Department of Genetics, Stanford University
Thu, Jun 5 · 14:00 UTC · Online
A hallmark pathological feature of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the depletion of RNA-binding protein TDP-43 from the nucleus of neurons in the brain and spinal cord. A major function of TDP-43 is as a repressor of cryptic exon inclusion during RNA splicing. By re-analyzing RNA-sequencing datasets from human FTD/ALS brains, we discovered dozens of novel cryptic splicing events in important neuronal genes. Single nucleotide polymorphisms in UNC13A are among the strongest hits associated with FTD and ALS in human genome-wide association studies, but how those variants increase risk for disease is unknown. We discovered that TDP-43 represses a cryptic exon-splicing event in UNC13A. Loss of TDP-43 from the nucleus in human brain, neuronal cell lines and motor neurons derived from induced pluripotent stem cells resulted in the inclusion of a cryptic exon in UNC13A mRNA and reduced UNC13A protein expression. The top variants associated with FTD or ALS risk in humans are located in the intron harboring the cryptic exon, and we show that they increase UNC13A cryptic exon splicing in the face of TDP-43 dysfunction. Together, our data provide a direct functional link between one of the strongest genetic risk factors for FTD and ALS (UNC13A genetic variants), and loss of TDP-43 function. Recent analyses have revealed even further changes in TDP-43 target genes, including widespread changes in alternative polyadenylation, impacting expression of disease-relevant genes (e.g., ELP1, NEFL, and TMEM106B) and providing evidence that alternative polyadenylation is a new facet of TDP-43 pathology.
March 2025
Spatio-temporal Regulation of Gene Expression in Neurons: Insights from Imaging mRNAs Live in Action
Sulagna Das· Assistant Professor, Emory University School of Medicine
Mon, Mar 3 · 19:00 UTC · Online
Molecular BiologyMolecular Neuroscience
February 2025
LRRK2 – a master regulator of neurodegeneration: acting on multiple systems including neuroinflammatory signaling, vesicular trafficking, and cell death pathways
Hardy Rideout· Biomedical Research Foundation, Academy of Athens
Fri, Feb 21 · 14:30 UTC · Online
The synaptic functions of Alpha Synuclein and Lrrk2
Subhojit Roy, MD, PhD· University of Wisconsin-Madison
Tue, Feb 18 · 04:30 UTC · Online
Alpha synuclein and Lrrk2 are key players in Parkinson's disease and related disorders, but their normal role has been confusing and controversial. Data from acute gene-editing based knockdown, followed by functional assays, will be presented.
Molecular BiologyMolecular Neuroscience
Defining Molecular Mechanisms Underlying Neurodegenerative Diseases
Celeste Karch, PhD· Washington University School of Medicine
Tue, Feb 4 · 04:30 UTC · Online
Molecular BiologyMolecular Neuroscience
January 2025
Neurobiological Pathways to Tau-dependent Pathology: Perspectives from flies to humans
Papanikolopoulou Katerina· Biomedical Sciences Research Centre "Alexander Fleming
Fri, Jan 24 · 14:00 UTC
The Role of GPCR Family Mrgprs in Itch, Pain, and Innate Immunity
Xinzhong Dong· Johns Hopkins University
Mon, Jan 13 · 06:00 UTC · Online
NeuroscienceNeuroimmunology
December 2024
Gene regulatory mechanisms of neocortex development and evolution
Mareike Albert· Center for Regenerative Therapies, Dresden University of Technology, Germany
Thu, Dec 12 · 16:00 UTC · Online
The neocortex is considered to be the seat of higher cognitive functions in humans. During its evolution, most notably in humans, the neocortex has undergone considerable expansion, which is reflected by an increase in the number of neurons. Neocortical neurons are generated during development by neural stem and progenitor cells. Epigenetic mechanisms play a pivotal role in orchestrating the behaviour of stem cells during development. We are interested in the mechanisms that regulate gene expression in neural stem cells, which have implications for our understanding of neocortex development and evolution, neural stem cell regulation and neurodevelopmental disorders.
Rett syndrome, MECP2 and therapeutic strategies
Rudolf Jaenisch· Whitehead Institute for Biomedical Research and Department of Biology, MIT, Cambridge, USA
Wed, Dec 11 · 12:15 UTC · Online
The development of the iPS cell technology has revolutionized our ability to study development and diseases in defined in vitro cell culture systems. The talk will focus on Rett Syndrome and discuss two topics: (i) the use of gene editing as an approach to therapy and (ii) the role of MECP2 in gene expression (i) The mutation of the X-linked MECP2 gene is causative for the disease. In a female patient, every cell has a wt copy that is, however, in 50% of the cells located on the inactive X chromosome. We have used epigenetic gene editing tools to activate the wt MECP2 allele on the inactive X chromosome. (ii) MECP2 is thought to act as repressor of gene expression. I will present data which show that MECP2 binds to Pol II and acts as an activator for thousands of genes. The target genes are significantly enriched for Autism related genes. Our data challenge the established model of MECP2’s role in gene expression and suggest novel therapeutic approaches.
October 2024
The molecular basis of prion diseases
Aguzzi Adriano· University of Zürich, Institute of Neuropathology
Fri, Oct 4 · 14:00 UTC · Online
July 2024
The cell biology of Parkinson’s disease: a role for primary cilia and synaptic vesicle pleomorphism in dopaminergic neurons
Nisha Mohd Rafiq· Interfaculty Institute of Biochemistry (IFIT), Tübingen University
Thu, Jul 18 · 16:15 UTC · Online
June 2024
In vivo scalable investigation of gene functions in the brain
Xin Jin· Scripps Research
Wed, Jun 26 · 05:00 UTC · Online
Rôle des vésicules extra cellulaires dans la propagation de la protéine Tau
Kevin Richetin· CHUV Lausanne, Switzerland
Thu, Jun 6 · 12:15 UTC · Online
May 2024
The role of mitopohagy in neuronal physiology
Pallikaras Konstantinos· Unit of Neurogenetcis and Ageing, Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Wed, May 29 · 14:00 UTC · Online
Beyond the synapse: SYNGAP1 in primary and motile cilia
Helen Willsey, PhD· University of California San Francisco
Sat, May 25 · 01:00 UTC · Online
Alternative Splicing and Isoforms: role in brain function and pathology
Mangoura Dimitra· Basic Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
Wed, May 15 · 14:00 UTC · Online
The Roles of Distinct Functions of SynGAP1 in SYNGAP1-Related Disorders
Richard Huganir· Johns Hopkins Medicine
Recorded
April 2024
Modeling human brain development and disease: the role of primary cilia
Kyrousi Christina· Medical School, National and Kapodistrian University of Athens, Athens, Greece
Wed, Apr 24 · 14:00 UTC · Online
Neurodevelopmental disorders (NDDs) impose a global burden, affecting an increasing number of individuals. While some causative genes have been identified, understanding the human-specific mechanisms involved in these disorders remains limited. Traditional gene-driven approaches for modeling brain diseases have failed to capture the diverse and convergent mechanisms at play. Centrosomes and cilia act as intermediaries between environmental and intrinsic signals, regulating cellular behavior. Mutations or dosage variations disrupting their function have been linked to brain formation deficits, highlighting their importance, yet their precise contributions remain largely unknown. Hence, we aim to investigate whether the centrosome/cilia axis is crucial for brain development and serves as a hub for human-specific mechanisms disrupted in NDDs. Towards this direction, we first demonstrated species-specific and cell-type-specific differences in the cilia-genes expression during mouse and human corticogenesis. Then, to dissect their role, we provoked their ectopic overexpression or silencing in the developing mouse cortex or in human brain organoids. Our findings suggest that cilia genes manipulation alters both the numbers and the position of NPCs and neurons in the developing cortex. Interestingly, primary cilium morphology is disrupted, as we find changes in their length, orientation and number that lead to disruption of the apical belt and altered delamination profiles during development. Our results give insight into the role of primary cilia in human cortical development and address fundamental questions regarding the diversity and convergence of gene function in development and disease manifestation. It has the potential to uncover novel pharmacological targets, facilitate personalized medicine, and improve the lives of individuals affected by NDDs through targeted cilia-based therapies.